Adverum Biotechnologies, Inc.

NASDAQ:ADVM

8 (USD) • At close November 8, 2024
Bedrijfsnaam Adverum Biotechnologies, Inc.
Symbool ADVM
Munteenheid USD
Prijs 8
Beurswaarde 166,407,200
Dividendpercentage 0%
52-weken bereik 6.38 - 29.7
Industrie Biotechnology
Sector Healthcare
CEO Dr. Laurent Fischer
Website https://www.adverum.com

An error occurred while fetching data.

Over Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.

Vergelijkbare Aandelen

Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

0.99 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

0.74 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

1.04 USD

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

ALZN

1.49 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

19.7 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

3.76 USD

Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

2.88 USD

PAVmed Inc. logo

PAVmed Inc.

PAVM

1.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)